Study on preventive effect of risedronate administration on aromatase inhibitor-induced bone mineral loss in the endoclinical therapy for postmenopausal breast cancer patients
Not Applicable
- Conditions
- Hormone-receptor positive, postmenopausal primary breast cancer
- Registration Number
- JPRN-UMIN000004375
- Lead Sponsor
- Graduate School of Medicine Kyoto University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 64
Inclusion Criteria
Not provided
Exclusion Criteria
1) Inflamatory breast cancer 2) Hypersensitivity to any reagents used in this trial. 3) Serious complications 4) Excess alcohol consumption 5) Habitual smoker 6) Family history of hip joint fracture 7) Active dental and/ or periodontal disease which requires treatment 8) Withdrawal of informed concent 9) Patients who are judged inappropriate for the clinical trial by doctors
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method change from baseline on 18 month in bone mineral density
- Secondary Outcome Measures
Name Time Method change from baseline on 18 month in bone turnover markers